Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses grows, but more slowly than its trailing trend

Q3 FY2026 operating expenses of $370.1M rose 17.7% year over year, behind the +22.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +10.0% a year.

Context

  • Operating expenses amounted to 138.8% of revenue in FY2025, down 27.0 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.7% toward the trailing-twelve-month pace of +22.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$370.1M+0.7% QoQ
Last fiscal yearDec 2025
$1.31B+12.1% YoY
LTMSep 2026
$1.51B+22.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year+12.1%——
3-year CAGR+10.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
1.31B USD
Year-over-year change
+12.1%
4-year CAGR
+12.1%

Operating Expenses vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 operating expenses of $1.51B is the 4th highest of the 9 companies compared; the peer median is $1.31B.
  • Its year-over-year change of +22.3% is the 4th highest of 9, against a peer median of +11.5%.
  • Operating expenses amounts to 157.1% of revenue for IONS, versus a peer median of 79.3%.
IONS Competitors Peer median
Operating Expenses for IONS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$902.93B +47406.7%+10.9%87.9%
BIIBBiogen Inc.LTM Jun 2026$5.46B +12.8%+0.2%54.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$2.83B +26.4%+15.3%58.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$1.51B +22.3%+10.0%157.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$1.4B -27.8%+14.1%64.3%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$1.21B +36.9%+21.2%169.6%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$1.12B +10.3%+3.8%167.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$712.31M -28.4%-10.0%70.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$319.11M -10.9%-0.7%482.8%
Peer median (excluding IONS) $1.31B+11.5%+7.3%79.3%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue810.46M587.37M787.65M705.14M944M
Cost of Revenue10.84M14.12M9.13M11.22M16M
Gross Profit799.61M573.25M778.51M693.92M928M
Gross Margin98.7%97.6%98.8%98.4%98.3%
Research & Development643M833M899.63M901.53M916M
Selling, General & Admin170.9M150.3M232.6M267.5M394M
Operating Expenses829.8M983.44M1.13B1.17B1.31B
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
EBITDA(5.19M)(227.76M)(235.87M)(353.72M)(284.31M)
EBITDA Margin-0.6%-38.8%-29.9%-50.2%-30.1%
Operating Income(30.19M)(410.19M)(353.73M)(475.08M)(382M)
Operating Margin-3.7%-69.8%-44.9%-67.4%-40.5%
Interest Income10.04M25.33M89.04M107.02M97.77M
Interest Expense9.35M8.12M81.46M90.45M90.54M
Other Income / Expenses1.04M152.21M19.77M15.01M2M
Income Before Tax(29.15M)(257.99M)(333.97M)(460.07M)(380M)
Pre-Tax Margin-3.6%-43.9%-42.4%-65.2%-40.3%
Income Tax Expense(551K)11.74M32.32M(6.17M)1M
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381M)
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (Basic)(0.20)(1.90)(2.56)(3.04)(2.38)
EPS (Diluted)(0.20)(1.90)(2.56)(3.04)(2.38)
Weighted Avg Shares141.02M141.85M143M149.51M160M
Weighted Avg Shares (Diluted)141.02M141.85M143.19M149.51M160M

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.